Ryan Deschner
Stock Analyst at Raymond James
(1.44)
# 3,276
Out of 4,735 analysts
7
Total ratings
57.14%
Success rate
-2.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $13.48 | +107.72% | 3 | Jan 14, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Outperform | $9 | $3.56 | +153.16% | 1 | Aug 30, 2024 | |
| LQDA Liquidia | Upgrades: Strong Buy | $27 | $13.62 | +98.24% | 2 | Aug 19, 2024 | |
| OMGA Omega Therapeutics | Initiates: Outperform | $12 | $0.50 | +2,300.00% | 1 | Jun 18, 2024 |
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $13.48
Upside: +107.72%
Trevi Therapeutics
Aug 30, 2024
Initiates: Outperform
Price Target: $9
Current: $3.56
Upside: +153.16%
Liquidia
Aug 19, 2024
Upgrades: Strong Buy
Price Target: $27
Current: $13.62
Upside: +98.24%
Omega Therapeutics
Jun 18, 2024
Initiates: Outperform
Price Target: $12
Current: $0.50
Upside: +2,300.00%